Abstract:Androgen receptor (AR) is a key contributing element in the prostate cancer (PCa) instigation, progression and it is among the vastly discovered target for prostate cancer. Numerous mechanisms trigger the expansion of CRPC among which the aberrant AR gene is considered as the prime factor. Recently three essential substitutions H875Y, F877L, and T878A are reported to cause resistance to Enzalutamide. However, no detailed study is available to explore the key events that contribute to the resistance. Hence, considering the applicability of structural bioinformatics and molecular simulation-based methods in the current study, we assessed the impact of these mutations on the binding of Enzalutamide. Using a long-run simulation approach the binding stability, residues flexibility, hydrogen bonding, and protein compactness for each complex were determined to reveal the dynamic variations induced by these mutations. We discovered that the binding mode of Enzalutamide is altered by these mutations which misstarget the key residues required for the antagonistic activity. Molecular simulation of each complex revealed that the wild type H11 and H12 are more flexible moving outside and provides more volume for the ligand optimization. In the mutant complexes, the H12 remained tighter pushing out enzaluta-mide from the key residues which then essentially misstarget the correct orientation for the antagonist activity. The binding free energy (BFE) for the wild type was computed to be-59.92 +/- 0.18 kcal/mol, for H875Y the BFE was-55.92 +/- 0.18 kcal/mol,-54.82 +/- 0.15 kcal/mol for F877L and-53.87 +/- 0.18 kcal/mol for T878A, which further demonstrate that these mutations have destabilized the binding of enzalutamide. The proteins' motion and FEL further validated the aforementioned findings where the wild type reported different dynamic features than the mutant complexes. In conclusion, this study provides a structural basis for the resistance to Enzaluta-mide, which can be used to design novel effective drugs using structure-based and rationale approaches.

Analysis of the binding modes of the first‐ and second‐generation antiandrogens with respect to F876L mutation

Structural and Molecular Insights into the Mechanism of Resistance to Enzalutamide by the Clinical Mutants in Androgen Receptor (AR) in Castration-Resistant Prostate Cancer (CRPC) Patients

Computational Analysis of Residue-Specific Binding Free Energies of Androgen Receptor to Ligands

Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds

Conformational dynamics of androgen receptors bound to agonists and antagonists

Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation

Discovery of Novel Anti‐Resistance AR Antagonists Guided by Funnel Metadynamics Simulation

Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations

Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator

Computational Alanine Scanning with Interaction Entropy for Protein-ligand Binding Free Energies.

Discovery of 5-Nitro-n-(3-(trifluoromethyl)phenyl) Pyridin-2-amine As a Novel Pure Androgen Receptor Antagonist Against Antiandrogen Resistance

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

Structural Insights into the Mechanism of Resistance to Bicalutamide by the Clinical Mutations in Androgen Receptor in Chemo-Treatment Resistant Prostate Cancer.

Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists

The Fluorescent Two-Hybrid Assay for Live-Cell Profiling of Androgen Receptor Modulators.

Effect of Mutations on Drug Resistance of Smoothened Receptor Toward Inhibitors Probed by Molecular Modeling

Research progress on prostate cancer drugs targeting different sites of androgen receptor

Exploring novel Apalutamide analogues as potential therapeutics for prostate cancer: design, molecular docking investigations and molecular dynamics simulation

Drug-resistance Mechanisms of Three Mutations in Anaplastic Lymphoma Kinase Against Two Inhibitors Based on MM/PBSA Combined with Interaction Entropy

Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling